NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
1.48
Dollar change
-0.04
Percentage change
-2.63
%
IndexRUT P/E- EPS (ttm)-1.47 Insider Own23.61% Shs Outstand70.99M Perf Week-2.63%
Market Cap105.09M Forward P/E- EPS next Y-1.56 Insider Trans-0.01% Shs Float54.24M Perf Month0.00%
Enterprise Value-45.63M PEG- EPS next Q-0.40 Inst Own80.22% Short Float11.75% Perf Quarter-2.63%
Income-103.28M P/S2.64 EPS this Y-12.41% Inst Trans-0.33% Short Ratio5.16 Perf Half Y-59.34%
Sales39.78M P/B0.54 EPS next Y8.70% ROA-28.77% Short Interest6.38M Perf YTD-58.89%
Book/sh2.75 P/C0.49 EPS next 5Y6.31% ROE-45.55% 52W High7.66 -80.68% Perf Year-69.48%
Cash/sh3.03 P/FCF- EPS past 3/5Y5.90% -8.92% ROIC-40.73% 52W Low1.09 36.41% Perf 3Y-79.30%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-8.06% 10.72% Gross Margin80.19% Volatility9.40% 9.19% Perf 5Y-
Dividend TTM- EV/Sales-1.15 EPS Y/Y TTM37.97% Oper. Margin-292.99% ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.70 Sales Y/Y TTM98.56% Profit Margin-259.60% RSI (14)48.83 Recom1.86
Dividend Gr. 3/5Y- - Current Ratio5.70 EPS Q/Q10.33% SMA20-3.52% Beta2.95 Target Price15.80
Payout- Debt/Eq0.33 Sales Q/Q138.17% SMA50-1.35% Rel Volume0.59 Prev Close1.52
Employees110 LT Debt/Eq0.30 EarningsMay 07 BMO SMA200-55.18% Avg Volume1.24M Price1.48
IPOOct 02, 2020 Option/ShortYes / Yes EPS/Sales Surpr.16.29% 61.80% Trades Volume728,171 Change-2.63%
Date Action Analyst Rating Change Price Target Change
Dec-19-24Upgrade Wells Fargo Equal Weight → Overweight $8 → $12
Nov-18-24Initiated Stephens Equal-Weight $4
Jan-29-24Upgrade JP Morgan Underweight → Neutral $6
Dec-13-23Upgrade Stifel Hold → Buy $2 → $12
Feb-24-23Upgrade Credit Suisse Underperform → Neutral $12 → $10
Feb-24-23Downgrade JP Morgan Neutral → Underweight $15 → $5
Nov-04-22Downgrade JP Morgan Overweight → Neutral $22 → $15
Oct-11-22Initiated Morgan Stanley Underweight $6
Apr-28-22Initiated Credit Suisse Underperform $10
Apr-11-22Downgrade BofA Securities Buy → Neutral $46 → $15
May-07-25 08:15AM
07:00AM
Apr-29-25 05:15PM
Mar-03-25 09:35AM
Feb-27-25 09:35AM
08:15AM Loading…
08:15AM
07:00AM
Feb-26-25 09:35AM
Feb-24-25 07:00AM
Jan-14-25 07:00AM
Jan-08-25 07:00AM
Jan-02-25 09:55AM
Dec-30-24 02:48PM
Dec-08-24 12:30PM
Nov-20-24 07:00AM
07:00AM Loading…
Nov-06-24 07:00AM
Nov-05-24 09:00AM
07:05AM
Oct-31-24 08:20AM
07:00AM
Oct-28-24 04:01PM
Oct-15-24 04:01PM
Oct-09-24 07:00AM
Sep-30-24 04:01PM
Sep-13-24 10:00AM
Sep-10-24 07:00AM
Sep-08-24 06:05PM
Sep-03-24 07:00AM
Aug-29-24 07:00AM
Aug-14-24 07:00AM
08:10AM Loading…
Aug-01-24 08:10AM
07:00AM
Jul-17-24 07:13AM
Jul-16-24 04:01PM
Jul-09-24 12:00PM
Jul-08-24 07:00AM
Jun-29-24 08:45PM
Jun-10-24 07:00AM
May-28-24 01:24PM
May-10-24 02:52PM
May-09-24 10:52AM
May-08-24 02:53PM
01:54PM
07:00AM
Apr-29-24 04:01PM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Mar-28-24 04:36AM
Mar-05-24 04:30PM
Mar-04-24 07:00AM
Feb-22-24 08:15AM
07:36AM
07:00AM
Feb-15-24 10:19AM
10:00AM
Jan-11-24 11:44AM
Jan-09-24 06:20PM
04:01PM
Jan-04-24 04:01PM
07:00AM
Jan-03-24 11:10AM
Jan-01-24 09:55AM
Dec-27-23 07:35PM
Dec-15-23 09:55AM
Dec-13-23 12:39PM
Dec-12-23 04:01PM
10:13AM
07:00AM
Nov-28-23 07:00AM
Nov-20-23 07:00AM
Nov-13-23 09:55AM
Nov-01-23 11:03AM
09:40AM
07:00AM
Oct-11-23 07:00AM
Sep-05-23 04:01PM
Aug-28-23 06:30PM
Aug-08-23 08:40AM
07:00AM
Aug-04-23 06:58AM
Jul-17-23 07:00AM
Jul-05-23 07:00AM
Jun-20-23 07:00AM
May-30-23 07:00AM
May-14-23 08:06AM
May-04-23 08:15AM
07:00AM
Apr-19-23 07:00AM
Apr-11-23 09:35AM
Mar-23-23 07:39AM
Feb-24-23 05:38AM
Feb-23-23 08:35AM
07:00AM
Feb-08-23 07:00AM
Jan-30-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 06:15PM
Jan-04-23 09:40AM
Jan-03-23 07:00AM
Nov-13-22 07:13AM
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyle Scott NChief Business OfficerFeb 18 '25Sale3.156692,107107,805Feb 18 04:55 PM
Boyle Scott NChief Business OfficerFeb 14 '25Sale3.154901,544110,842Feb 18 04:55 PM
Salter MalcolmDirectorNov 18 '24Proposed Sale4.1913,00054,532Nov 18 04:43 PM
Salter MalcolmDirectorOct 18 '24Proposed Sale6.4113,00083,321Oct 18 04:45 PM
Salter MalcolmDirectorOct 11 '24Proposed Sale5.388,56146,061Oct 11 05:37 PM